Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M.

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...